MAPT and Alzheimer disease: Clinical studies and trials have adopted PET scans as in vivo evidence of AD pathology, which greatly limits population reach not only due to the high costs of imaging, but also because PET facilities must be located near a cyclotron, as the half‐lives of amyloid and tau tracers are ≈110 min.34, 36